SFJ

Apocalypse Manufacturing Achieves Nirvana With Latest 850 Horsepower Build

Retrieved on: 
Friday, September 29, 2023
ESPN, EV, Torque, Ford, SFJ, Lost City, Paramount, Masculinity, TMZ, Ram, Love, Apocalypse, Ford Bronco, Erosion, Nirvana, Bucking horse, Heavy equipment, Jeep

FORT LAUDERDALE, Fla. , Sept. 29, 2023 /PRNewswire/ -- Apocalypse Manufacturing, the company known for constructing innovative trucks to combat all on/off-road scenarios, has announced the launch of their most ambitious project to date: the Apocalypse Nirvana. This groundbreaking off-road and on-road vehicle showcases the company's commitment to exploring all powerplant options, while continuing to push their functions to the limit.

Key Points: 
  • FORT LAUDERDALE, Fla. , Sept. 29, 2023 /PRNewswire/ -- Apocalypse Manufacturing, the company known for constructing innovative trucks to combat all on/off-road scenarios, has announced the launch of their most ambitious project to date: the Apocalypse Nirvana.
  • Spec-wise the Nirvana comes in at a height of 81", a width of 91" and a total length of 214".
  • The Apocalypse Nirvana is not just a 4x4 powerhouse, it's a work of art.
  • For more information about Apocalypse Manufacturing and their exceptional range of custom vehicles, please visit www.Apocalypse6x6.com or SoFloCustoms.com.

The Apocalypse Super Truck - Rescues The Boring Exotic Sportscar Market

Retrieved on: 
Wednesday, May 17, 2023
ESPN, Harman Kardon, Travel, SFJ, Lost City, Paramount, TMZ, Beauty, Stadium Super Trucks, Apocalypse, Sport, Sand, Road

FORT LAUDERDALE, Fla., May 17, 2023 /PRNewswire/ -- Apocalypse Manufacturing, the company known for constructing innovative trucks to combat all on/off-road scenarios, have taken their massively successful Juggernaut 6x6 and turned it into a 4x4 – behold the Super Truck. The Super Truck is sheer power, boasting a modified Hellcat V8 supercharged 6.2L powerplant that churns out 850 horsepower and does so with fulltime four-wheel drive. Sitting on 40" tires and 22" SFJ rims, the Super Truck comes in at a towering height of 83", a width of 98" and a total length of 240".

Key Points: 
  • The Super Truck is sheer power, boasting a modified Hellcat V8 supercharged 6.2L powerplant that churns out 850 horsepower and does so with fulltime four-wheel drive.
  • Sitting on 40" tires and 22" SFJ rims, the Super Truck comes in at a towering height of 83", a width of 98" and a total length of 240".
  • "There isn't another 4x4 on the market like the Apocalypse Supertruck," said Joseph Ghattas, owner and engineer.
  • "There isn't another 4x4 on the market that has the speed, size, reliability, comfort, space and off-road/on-road features as our latest creation."

SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent

Retrieved on: 
Thursday, May 11, 2023
Biologics license application, US Foods, Bleeding, Acute coronary syndrome, SERB, The New England Journal of Medicine, Stroke, CAD, Breakthrough therapy, SFJ, AstraZeneca, Ticagrelor, Bentracimab, Acquisition, Patient, Physician, Risk, SAN, Coronary artery disease, FDA, Death, BLA, Food, Pharmaceutical industry

PHILADELPHIA and SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ.

Key Points: 
  • PHILADELPHIA and SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ.
  • Bentracimab is a novel, monoclonal antibody fragment designed to reverse the antiplatelet activity of ticagrelor.
  • Ticagrelor, marketed by AstraZeneca as Brilinta®, is a reversible oral P2Y12 platelet inhibitor for patients who have suffered a heart attack or stroke, or who have acute coronary syndromes or coronary artery disease (CAD).
  • Leopoldo Zambeletti acted as advisor for SFJ, and Evercore acted as advisor for SERB.

SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals

Retrieved on: 
Tuesday, January 17, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Title 11 of the United States Code, SFJ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biologics license application, Bankruptcy, Food, Patient, United States bankruptcy court, Sale, Optimism, Pharmaceutical industry, Risk management, Bentracimab

SFJ Pharmaceuticals (“SFJ” or the “company”) today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) to SFJ.

Key Points: 
  • SFJ Pharmaceuticals (“SFJ” or the “company”) today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) to SFJ.
  • Since 2020, SFJ and PhaseBio have worked on co-developing Bentracimab (formerly known as PB2452), which has the potential to address a significant unmet need for patients in major bleeding and urgent surgery situations, and SFJ retains deep clinical and commercial expertise related to the Bentracimab program.
  • SFJ expects to file the Biologics License Application for Bentracimab with the U.S. Food and Drug Administration in mid-2023.
  • Robert DeBenedetto, Chief Executive Officer of SFJ, said, “We appreciate the diligent work of all parties to reach agreement on the transfer of Bentracimab assets to SFJ.

The Hollywood Reporter Taps Mesfin Fekadu as Senior Music Editor

Retrieved on: 
Tuesday, November 29, 2022
Journalism, National Magazine Awards, Culture, Editing, Live Nation Entertainment, Pleasure, Associated Press, Close Up with The Hollywood Reporter, New York Press Club, University, Multimedia, New York Fashion Week, Rising Star Award, Empowerment, Fikadu, Press, Society, William Senior (journalist), AP, The, The Rolling Stones, Interest group, News, American Society of Magazine Editors, Associated, THR, Grammy Awards, Death, Daytime Emmy Awards, SFJ, Music, Film

LOS ANGELES, Nov. 29, 2022 /PRNewswire/ --The Hollywood Reporter (THR)is expanding its music coverage hiring MesfinFekadu as its Senior Music Editor.

Key Points: 
  • LOS ANGELES, Nov. 29, 2022 /PRNewswire/ --The Hollywood Reporter (THR)is expanding its music coverage hiring MesfinFekadu as its Senior Music Editor.
  • Fekadu will start his new position on December 5th and report into David Katz, THR's Executive Editor.
  • Fekadu, joined the AP in 2008 in the video entertainment department; he later became a music writer in 2012 and music editor in 2014 .
  • In 2020, The Hollywood Reporter won the National Magazine Award for General Excellence, Special Interest, awarded by the American Society of Magazine Editors.

PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Omni, Bankruptcy, LinkedIn, CA, U.S. Securities and Exchange Commission, Time, Hypertension, Sale, SEC, Bleeding, Achievement, Review, SFJ, Chapter 11, Title 11, United States Code, United States bankruptcy court, Bankruptcy Code, Solution, District, Patient, Bentracimab, Contract, JMB, Research, Program, Partnership, Cooley LLP, Private Securities Litigation Reform Act, Acquisition, Board, Pharmacokinetics, Intention, PHAS, Insolvency and Bankruptcy Code, 2016, Forward-looking statement, Degenerative disease, Ticagrelor, LLP, Security (finance), Sales, Pharmaceutical industry, Stifel

As part of the case, PhaseBio also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.

Key Points: 
  • As part of the case, PhaseBio also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.
  • PhaseBio has filed a series of motions with the court seeking to ensure the continuation of normal operations during this process.
  • For this process, PhaseBio has the support of JMB Capital Partners, that has made a financing commitment of $15 million.
  • PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases.

PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, August 12, 2022
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Other Health, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, PHAS, Disclosure, Chronic kidney disease, The New England Journal of Medicine, Pharmacokinetics, Forward-looking statement, Bentracimab, CA, Private Securities Litigation Reform Act, Clinical trial, IND, Research, Breakthrough therapy, Degenerative disease, Patient, Bleeding, SFJ, Aldosterone, Program, Partnership, GMP, American Heart Association, Aspirin, BLA, Ticagrelor, Hypertension, LinkedIn, Heart failure, Food, EMA, Pharmaceutical industry

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities.
  • The second quarter of 2022 marked a period of continued progress for PhaseBio, said Jonathan Mow, Chief Executive Officer of PhaseBio Pharmaceuticals.
  • PhaseBio expects that SFJ will fund or reimburse an additional $21.0 million of clinical trial costs and other expenses.
  • PB6440 IND enabling studies continue to advance: In the second quarter of 2022, PhaseBio completed the development and optimization of a robust manufacturing process to support anticipated upcoming proof-of-concept trials, positioning the program for initial GMP manufacturing runs in the fourth quarter of 2022.

SoFlo Jeeps Adds Lift, Rims, Tires And 700+ Horsepower Engine To Transform All New Ford Bronco Into the SoFlo Stallion

Retrieved on: 
Thursday, December 9, 2021
Ford Bronco, King Ranch, Ford Motor Company, Research, Love, Miami, SFJ, Weather, Road

FORT LAUDERDALE, Fla., Dec. 9, 2021 /PRNewswire/ --Behold the SoFlo Stallion, SoFlo Jeeps' answer to the long-awaited Ford Bronco.

Key Points: 
  • FORT LAUDERDALE, Fla., Dec. 9, 2021 /PRNewswire/ --Behold the SoFlo Stallion, SoFlo Jeeps' answer to the long-awaited Ford Bronco.
  • Heralded as the hottest, most coveted SUV/truck of 2021, the Ford Bronco gets a full enhancement from the world's premier customization specialists.
  • MOTORING: In order to ensure the SoFlo Stallion is a thoroughbred, customizations to the truck can include a 700+ horsepower supercharged V8 Coyote 5.0L motor upgrade.
  • Click on the links below to watch the SoFlo Stallion in action:

PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 10, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, MPH, Desun Hospital & Heart Institute, Director, Clinical trial, Food, Harvard Medical School, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disclosure, Review, Aspirin, Hypertension, Probability, SFJ, Research, Forward-looking statement, Headache, American Heart, Hypertensive emergency, Patient, Bleeding, FDA, Bentracimab, Private Securities Litigation Reform Act, Center, VIP, Union, PHAS, National Medical Products Administration, Twitter, U.S. Securities and Exchange Commission, Pharmacokinetics, European Union, BLA, Biologics license application, CA, Board, Partnership, Center for Drug Evaluation and Research, LinkedIn, Pivotal, Investigational New Drug, Bruise, Ticagrelor, Pamlab, IND, Pharmaceutical industry, Management

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported third-quarter 2021 financial results.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported third-quarter 2021 financial results.
  • Details about the upcoming presentation were set forth in PhaseBios press release on October 6, 2021 .
  • PhaseBio is commencing preparation of the BLA and, subject to favorable results being observed, is targeting a BLA submission to the FDA in mid-2022.
  • Risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021.

PhaseBio Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, August 12, 2021
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Forward-looking statement, Aspirin, Clinical trial, Achievement, Dabigatran, Partnership, Dawn of X, Research, Bleeding, Union, United, Safety, Commonwealth, Review, International Society, Center, CA, Company, Food, LinkedIn, Private Securities Litigation Reform Act, IND, FDA, Center for Drug Evaluation and Research, Commercial, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pamlab, VIP, National Medical Products Administration, U.S. Securities and Exchange Commission, Pharmacokinetics, Conference, PHAS, Hypertensive emergency, Hypertension, International Society for Pharmacoeconomics and Outcomes Research, SFJ, Disclosure, CDE, BLA, Probability, European, Patient, Reversal, Twitter, NMPA, Commercialization, American College, American College of Cardiology, Pharmaceutical industry

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported second-quarter 2021 financial results.

Key Points: 
  • PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today provided an update on corporate activities and reported second-quarter 2021 financial results.
  • We believe these clinical and strategic milestones position PhaseBio to finish 2021 with significant momentum.
  • Completed Enrollment in Bentracimab Phase 2b trial: In August 2021, PhaseBio announced the completion of enrollment in the randomized, double-blind, placebo-controlled Phase 2b trial of bentracimab.
  • PhaseBio and SFJ anticipate enrolling the first patients at sites in China later in 2021.